Here’s what you need to know:
1. Kovanaze was approved by the FDA in June 2016.
2. Unlike standard dental anesthetic, which is administered through needle injection, Kovanaze is administered through a nasal spray.
3. Kovanaze is a topic, tooth nerve anesthetic containing tetracaineHCl (an ester local anesthetic) and oxymetazolineHCl (a vasoconstrictor).
4. The anesthetic is meant for restoratives procedures on Teeth 4 through 13 and A through J in adults and children who weigh more than 40 kilograms.
5. St. Renatus announced the launch of Kovanaze at the 2016 American Dental Association Meeting.
More articles on anesthesia:
AAN inducts Dr. Joseph Pellegrini: 3 things to know
Anesthesia Business Consultants launches MACRA guidance platform: 3 notes
Does local anesthetic choice impact outpatient foot surgery cost? 3 study insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.